| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (NCT05119335) | NiKang Therapeutics, Inc. | 2021-10-26 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma (NCT03229278) | Rutgers, The State University of New Jersey | 2017-10-03 |
| Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer (NCT03092856) | University of Southern California | 2017-07-19 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
| TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors (NCT02650635) | Mayo Clinic | 2016-02-05 |
| Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations (NCT02646319) | Mayo Clinic | 2016-01-01 |
| Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer (NCT02664883) | University of Southern California | 2015-09-08 |
| Immunotherapy Study for Metastatic Renal Cell Cancer (NCT02035358) | NewLink Genetics Corporation | 2015-05-01 |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer (NCT02542202) | University of Chicago | 2015-05-01 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
| Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer (NCT02318771) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2015-02-05 |
| Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer (NCT02170389) | Roswell Park Cancer Institute | 2014-10-14 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer (NCT01767636) | Mayo Clinic | 2013-05-16 |
| Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer (NCT01727076) | National Cancer Institute (NCI) | 2013-02-15 |
| Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer (NCT01727089) | National Cancer Institute (NCI) | 2012-11-01 |
| Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery (NCT01688973) | National Cancer Institute (NCI) | 2012-08-20 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (NCT01638533) | National Cancer Institute (NCI) | 2012-08-03 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01548482) | National Cancer Institute (NCI) | 2012-03-01 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (NCT01522820) | Roswell Park Cancer Institute | 2012-03-01 |
| Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy (NCT01198158) | National Cancer Institute (NCI) | 2010-09-15 |
| A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy (NCT01141569) | National Cancer Institute (NCI) | 2010-06-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery (NCT01061411) | Roswell Park Cancer Institute | 2010-02-06 |
| Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer (NCT00378703) | National Cancer Institute (NCI) | 2007-09-14 |
| Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors (NCT00499135) | National Cancer Institute (NCI) | 2007-05-22 |
| Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery (NCT00227760) | National Cancer Institute (NCI) | 2005-12-01 |
| Vorinostat in Treating Patients With Kidney Cancer (NCT00278395) | National Cancer Institute (NCI) | 2005-10-01 |
| Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer (NCT00121251) | National Cancer Institute (NCI) | 2005-06-03 |
| Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer (NCT00126594) | National Cancer Institute (NCI) | 2005-06-01 |
| Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer (NCT00126503) | National Cancer Institute (NCI) | 2005-05-01 |
| Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer (NCT00126490) | National Cancer Institute (NCI) | 2005-03-01 |
| Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer (NCT00083109) | National Cancer Institute (NCI) | 2004-03-01 |